ValuEngine upgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.
A number of other research firms have also commented on CLLS. BidaskClub lowered shares of Cellectis from a sell rating to a strong sell rating in a research report on Saturday, July 14th. Zacks Investment Research lowered shares of Cellectis from a buy rating to a hold rating in a research report on Tuesday, July 10th. Finally, Barclays initiated coverage on shares of Cellectis in a research report on Monday, July 16th. They issued an overweight rating and a $50.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $49.75.
NASDAQ CLLS traded up $0.19 during trading on Thursday, reaching $26.82. The company’s stock had a trading volume of 103,449 shares, compared to its average volume of 152,703. Cellectis has a 1-year low of $22.62 and a 1-year high of $38.85.
Cellectis (NASDAQ:CLLS) last posted its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.45. Cellectis had a negative net margin of 281.38% and a negative return on equity of 25.46%. The firm had revenue of $8.34 million during the quarter, compared to analysts’ expectations of $9.43 million. As a group, analysts anticipate that Cellectis will post -2.15 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Cellectis in the third quarter valued at approximately $129,000. Ladenburg Thalmann Financial Services Inc. increased its position in Cellectis by 1,300.0% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,600 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 5,200 shares during the period. Commonwealth Equity Services LLC bought a new position in Cellectis during the second quarter worth $237,000. UBS Group AG increased its position in Cellectis by 143.1% during the first quarter. UBS Group AG now owns 15,383 shares of the biotechnology company’s stock worth $485,000 after acquiring an additional 9,054 shares during the period. Finally, Prosight Management LP bought a new position in Cellectis during the second quarter worth $548,000. 27.10% of the stock is currently owned by institutional investors.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Read More: What is the Dow Jones Industrial Average (DJIA)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.